1. EMA - Committee for Medicinal Products for Human Use (CHMP). Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/CPMP/EWP/280/96 Corr1) [Internet]. 2014 [cited 2020 Jan 16]. Available from: www.ema.europa.eu/contact.
2. Fda. Bioavailability studies submitted in NDAs or INDs-general considerations guidance for industry [Internet]. 2019 [cited 2020 Jan 28]. Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.
3. Taylor K, Aulton M Aulton’s pharmaceutics - 4th edition [Internet]. 2013 [cited 2020 Jan 28]. Available from: https://www.elsevier.com/books/aultons-pharmaceutics/aulton/978-0-7020-4290-4.
4. Critical factors in the release of drugs from sustained release hydrophilic matrices
5. Methodology of oral formulation selection in the pharmaceutical industry